PRMT1 driven PTX3 regulates ferritinophagy in glioma.

ABSTRACT

Mutations in the Krebs cycle enzyme IDH1 (isocitrate dehydrogenase (NADP(+)) 1) are associated with better prognosis in gliomas. Though IDH1 mutant (IDH1R132H) tumors are characterized by their antiproliferative signatures maintained through hypermethylation of DNA and chromatin, mechanisms affecting cell death pathways in these tumors are not well elucidated. On investigating the crosstalk between the IDH1 mutant epigenome, ferritinophagy and inflammation, diminished expression of PRMT1 (protein arginine methyltransferase 1) and its associated asymmetric dimethyl epigenetic mark H4R3me2a was observed in IDH1R132H gliomas. Reduced expression of PRMT1 was concurrent with diminished levels of PTX3, a key secretory factor involved in cancer-related inflammation. Lack of PRMT1 H4R3me2a in IDH1 mutant glioma failed to epigenetically activate the expression of PTX3 with a reduction in YY1 (YY1 transcription factor) binding on its promoter. Transcriptional activation and subsequent secretion of PTX3 from cells was required for maintaining macroautophagic/autophagic balance as pharmacological or genetic ablation of PTX3 secretion in wild-type IDH1 significantly increased autophagic flux. Additionally, PTX3-deficient IDH1 mutant gliomas exhibited heightened autophagic signatures. Furthermore, we demonstrate that the PRMT1-PTX3 axis is important in regulating the levels of ferritin genes/iron storage and inhibition of this axis triggered ferritinophagic flux. This study highlights the conserved role of IDH1 mutants in augmenting ferritinophagic flux in gliomas irrespective of genetic landscape through inhibition of the PRMT1-PTX3 axis. This is the first study describing ferritinophagy in IDH1 mutant gliomas with mechanistic details. Of clinical importance, our study suggests that the PRMT1-PTX3 ferritinophagy regulatory circuit could be exploited for therapeutic gains.Abbreviations 2-HG D-2-hydroxyglutarate; BafA1 bafilomycin A1; ChIP chromatin immunoprecipitation; FTH1 ferritin heavy chain 1; FTL ferritin light chain; GBM glioblastoma; HMOX1/HO-1 heme oxygenase 1; IHC immunohistochemistry; IDH1 isocitrate dehydrogenase(NADP(+))1; MDC monodansylcadaverine; NCOA4 nuclear receptor coactivator 4; NFE2L2/Nrf2 NFE2 like bZIP transcription factor 2; PTX3/TSG-14 pentraxin 3; PRMT protein arginine methyltransferase; SLC40A1 solute carrier family 40 member 1; Tan IIA tanshinone IIA; TCA trichloroacetic acid; TEM transmission electron microscopy; TNF tumor necrosis factor.